Table 1.
Patients baseline characteristics at study inclusion
| All(n = 21) | Group 1(n = 8) | Group2(n = 13) | P = | |
|---|---|---|---|---|
| Age (years) | 47.9 ± 11.3 | 47.3 ± 11.8 | 48.4 ± 11.5 | 0.71 |
| Male/female | 12/9 | 4/4 | 8/5 | |
| Time after engraftment (months) | 6 ± 3.1 | 6.3 ± 3.4 | 5.5 ± 2.8 | 0.71 |
| Baseline creatinine (mg/dL) | 1.5 ± 0.42 | 1.57 ± 0.46 | 1.45 ± 0.41 | 0.64 |
| Baseline GFR (mL/min) | 44.9 ± 9.9 | 42.2 ± 10.2 | 46.5 ± 9.8 | 0.33 |
| Immunosuppression at the time of inclusion | ||||
| Ciclosporin/through level (ng/ml) | N = 10 (83.9 ± 14.5) |
N = 5 (85.6 ± 17.6) |
N = 5 (81.7 ± 12.4) |
0.72 |
| Tacrolimus/through level (ng/ml) | N = 11 (9.1 ± 1.7) |
N = 3 (9.2 ± 2.4) |
N = 8 (9.1 ± 1.4) |
0.73 |
| Prednisone frequency/dose (mg/day) | N = 7 (4.4 ± 1.5) | N = 5 (5 ± 0) | N = 2 (3 ± 2.8) | |
Values are given as mean ± SD.